MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System and ...
--CY 2026 Outpatient Prospective Payment System (OPPS) Final Rule moves RNS replacement procedures to highest-paying neurostimulator APC-- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company ...
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy, affecting a significant proportion of patients who develop drug-resistant epilepsy. Surgical interventions, particularly ...
NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
ATLANTA -- Are neurostimulators implanted within the brain a better approach in epilepsy than less-invasive vagus nerve stimulation (VNS)? That depends, a researcher said. Real-world data from two ...
-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures -- The PMA-S is ...
-- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to submit NAUTILUS PMA Supplement to ...
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy, affecting a significant proportion of patients who develop drug-resistant epilepsy. Surgical interventions, particularly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results